264 related articles for article (PubMed ID: 25934709)
1. Rho Kinase Inhibitor Fasudil Suppresses the Vasculogenic Mimicry of B16 Mouse Melanoma Cells Both In Vitro and In Vivo.
Xia Y; Cai XY; Fan JQ; Zhang LL; Ren JH; Chen J; Li ZY; Zhang RG; Zhu F; Wu G
Mol Cancer Ther; 2015 Jul; 14(7):1582-90. PubMed ID: 25934709
[TBL] [Abstract][Full Text] [Related]
2. RhoA/ROCK pathway inhibition by fasudil suppresses the vasculogenic mimicry of U2OS osteosarcoma cells in vitro.
Xia Y; Cai X; Fan J; Zhang L; Li Z; Ren J; Wu G; Zhu F
Anticancer Drugs; 2017 Jun; 28(5):514-521. PubMed ID: 28225457
[TBL] [Abstract][Full Text] [Related]
3. Rho-kinase inhibitor, fasudil, suppresses glioblastoma cell line progression in vitro and in vivo.
Deng L; Li G; Li R; Liu Q; He Q; Zhang J
Cancer Biol Ther; 2010 Jun; 9(11):875-84. PubMed ID: 20364104
[TBL] [Abstract][Full Text] [Related]
4. The role of sema4D in vasculogenic mimicry formation in non-small cell lung cancer and the underlying mechanisms.
Xia Y; Cai XY; Fan JQ; Zhang LL; Ren JH; Li ZY; Zhang RG; Zhu F; Wu G
Int J Cancer; 2019 May; 144(9):2227-2238. PubMed ID: 30374974
[TBL] [Abstract][Full Text] [Related]
5. Rho kinase inhibitor fasudil suppresses migration and invasion though down-regulating the expression of VEGF in lung cancer cell line A549.
Zhu F; Zhang Z; Wu G; Li Z; Zhang R; Ren J; Nong L
Med Oncol; 2011 Jun; 28(2):565-71. PubMed ID: 20300976
[TBL] [Abstract][Full Text] [Related]
6. Fasudil suppresses fibrosarcoma growth by stimulating secretion of the chemokine CXCL14/BRAK.
Miyamoto C; Maehata Y; Ozawa S; Ikoma T; Kubota E; Izukuri K; Kato Y; Hata R; Lee MC
J Pharmacol Sci; 2012; 120(3):241-9. PubMed ID: 23099322
[TBL] [Abstract][Full Text] [Related]
7. Fasudil inhibits prostate cancer-induced angiogenesis in vitro.
Chen W; Mao K; Hua-Huy T; Bei Y; Liu Z; Dinh-Xuan AT
Oncol Rep; 2014 Dec; 32(6):2795-802. PubMed ID: 25333508
[TBL] [Abstract][Full Text] [Related]
8. Antiangiogenic properties of fasudil, a potent Rho-Kinase inhibitor.
Hata Y; Miura M; Nakao S; Kawahara S; Kita T; Ishibashi T
Jpn J Ophthalmol; 2008; 52(1):16-23. PubMed ID: 18369695
[TBL] [Abstract][Full Text] [Related]
9. The Rho kinase inhibitor fasudil inhibits tumor progression in human and rat tumor models.
Ying H; Biroc SL; Li WW; Alicke B; Xuan JA; Pagila R; Ohashi Y; Okada T; Kamata Y; Dinter H
Mol Cancer Ther; 2006 Sep; 5(9):2158-64. PubMed ID: 16985048
[TBL] [Abstract][Full Text] [Related]
10. The Rho kinase inhibitor fasudil augments the number of functional endothelial progenitor cells in ex vivo cultures.
O E; Ahn HY; Kim HK; You JC; Shin JC; Joe YA
Int J Mol Med; 2011 Sep; 28(3):357-63. PubMed ID: 21567077
[TBL] [Abstract][Full Text] [Related]
11. Fasudil hydrochloride hydrate, a Rho-kinase inhibitor, suppresses 5-hydroxytryptamine-induced pulmonary artery smooth muscle cell proliferation via JNK and ERK1/2 pathway.
Chen XY; Dun JN; Miao QF; Zhang YJ
Pharmacology; 2009; 83(2):67-79. PubMed ID: 19052484
[TBL] [Abstract][Full Text] [Related]
12. Fasudil inhibits vascular endothelial growth factor-induced angiogenesis in vitro and in vivo.
Yin L; Morishige K; Takahashi T; Hashimoto K; Ogata S; Tsutsumi S; Takata K; Ohta T; Kawagoe J; Takahashi K; Kurachi H
Mol Cancer Ther; 2007 May; 6(5):1517-25. PubMed ID: 17513600
[TBL] [Abstract][Full Text] [Related]
13. Fasudil protects cultured N1E-115 cells against lysophosphatidic acid-induced neurite retraction through inhibition of Rho-kinase.
Satoh S; Kawasaki K; Hitomi A; Ikegaki I; Asano T
Brain Res Bull; 2011 Feb; 84(2):174-7. PubMed ID: 21126559
[TBL] [Abstract][Full Text] [Related]
14. HA1077, a Rho kinase inhibitor, suppresses glioma-induced angiogenesis by targeting the Rho-ROCK and the mitogen-activated protein kinase kinase/extracellular signal-regulated kinase (MEK/ERK) signal pathways.
Nakabayashi H; Shimizu K
Cancer Sci; 2011 Feb; 102(2):393-9. PubMed ID: 21166955
[TBL] [Abstract][Full Text] [Related]
15. Rho kinase inhibition by fasudil ameliorates diabetes-induced microvascular damage.
Arita R; Hata Y; Nakao S; Kita T; Miura M; Kawahara S; Zandi S; Almulki L; Tayyari F; Shimokawa H; Hafezi-Moghadam A; Ishibashi T
Diabetes; 2009 Jan; 58(1):215-26. PubMed ID: 18840783
[TBL] [Abstract][Full Text] [Related]
16. Fasudil attenuates lipopolysaccharide-induced acute lung injury in mice through the Rho/Rho kinase pathway.
Li Y; Wu Y; Wang Z; Zhang XH; Wu WK
Med Sci Monit; 2010 Apr; 16(4):BR112-118. PubMed ID: 20357711
[TBL] [Abstract][Full Text] [Related]
17. ROCK inhibitor fasudil attenuated high glucose-induced MCP-1 and VCAM-1 expression and monocyte-endothelial cell adhesion.
Li H; Peng W; Jian W; Li Y; Li Q; Li W; Xu Y
Cardiovasc Diabetol; 2012 Jun; 11():65. PubMed ID: 22694757
[TBL] [Abstract][Full Text] [Related]
18. The Rho-kinase inhibitor inhibits proliferation and metastasis of small cell lung cancer.
Yang X; Di J; Zhang Y; Zhang S; Lu J; Liu J; Shi W
Biomed Pharmacother; 2012 Apr; 66(3):221-7. PubMed ID: 22425182
[TBL] [Abstract][Full Text] [Related]
19. Fasudil inhibits lysophosphatidic acid-induced invasiveness of human ovarian cancer cells.
Ogata S; Morishige K; Sawada K; Hashimoto K; Mabuchi S; Kawase C; Ooyagi C; Sakata M; Kimura T
Int J Gynecol Cancer; 2009 Dec; 19(9):1473-80. PubMed ID: 19955921
[TBL] [Abstract][Full Text] [Related]
20. The Rho kinase inhibitor fasudil inhibits the migratory behaviour of 95-D lung carcinoma cells.
Yang X; Liu Y; Zong Z; Tian D
Biomed Pharmacother; 2010 Jan; 64(1):58-62. PubMed ID: 19879105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
